Adrian Murray Brunt

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial

Adrian Murray Brunt, Joanne Haviland, Duncan Wheatley et al. · The Lancet · 2020 · 1.1K citations · Full text

Medicine, Oncology, Surgery +17

Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial

Charlotte E. Coles, Clare Griffin, Anna M. Kirby et al. · The Lancet · 2017 · 612 citations · Full text

Medicine, Oncology, Radiation Oncology +17

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

Aron Goldhirsch, Richard D. Gelber, Martine Piccart et al. · The Lancet · 2013 · 501 citations

Medicine, Oncology, Breast Oncology +13

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial

Peter Schmid, Jacinta Abraham, Stephen Chan et al. · Journal of Clinical Oncology · 2019 · 389 citations · Full text

Medicine, Oncology, Pharmacology +16

Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer

Adrian Murray Brunt, Joanne Haviland, Mark Sydenham et al. · Journal of Clinical Oncology · 2020 · 300 citations · Full text

Medicine, Oncology, Radiation Oncology +8